Screening for colorectal cancer with immunochemical faecal occult blood tests

Digestive and Liver Disease

Volumn 44, Issue 12, 2012, Pages 967-973

  Faivre, Jean ^a   Dancourt, Vincent ^a   Lejeune, Catherine ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Colorectal cancer; Immunochemical faecal occult blood tests; Screening

Indexed keywords

CANCER MORTALITY; CANCER SCREENING; COLORECTAL ADENOMA; COLORECTAL CANCER; DIAGNOSTIC VALUE; FECES ANALYSIS; HUMAN; IMMUNOCHEMISTRY; OCCULT BLOOD TEST; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; EUROPE; GUAIAC; HUMANS; IMMUNOCHROMATOGRAPHY; INDICATORS AND REAGENTS; JAPAN; MASS SCREENING; NORTH AMERICA; OCCULT BLOOD; PATIENT ACCEPTANCE OF HEALTH CARE; SENSITIVITY AND SPECIFICITY;

EID: 84868300937     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.07.004     Document Type: Review

References (41)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010, 127:2893-2917.
2. Berrino F., De Angelis R., Sant M., et al. EUROCARE Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncology 2007, 8:773-783.
3. Hill M.J., Morson B.C., Bussey H.J. Aetiology of adenoma-carcinoma sequence in large bowel. Lancet 1978, 311:245-247.
4. Kronborg O., Fenger C., Olsen J., et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348:1467-1471.
5. Hardcastle J.D., Chamberlain J.O., Robinson M.H., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348:1472-1477.
6. Lindholm E., Brevinge H., Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. British Journal of Surgery 2008, 95:1029-1036.
7. Faivre J., Dancourt V., Lejeune C., et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004, 126:1674-1680.
8. Mandel J.S., Bond J.H., Church T.R., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. New England Journal of Medicine 1993, 328:1365-1371.
9. Council of the European Union. Council recommendation of 2 December 2003 on cancer screening. Official Journal of the European Union. 2003/878/EC, L327/34-38.
10. Hundt S., Haug U., Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Annals of Internal Medicine 2009, 150:162-169.
11. Faivre J, Dancourt V, Denis B, et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. European Journal of Cancer; , in press. http://www.sciencedirect.com/science/article/pii/S0959804912003486.
12. van Rossum L.G., van Rijn A.F., van Oijen M.G., et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. International Journal of Cancer 2009, 125:746-750.
13. Grazzini G., Ventura L., Zappa M., et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 2010, 59:1511-1515.
14. Guittet L., Guillaume E., Levillain R., et al. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening. Cancer Epidemiology, Biomarkers and Prevention 2011, 20:1492-1501.
15. van Rossum L.G., van Rijn A.F., Laheij R.J., et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008, 135:82-90.
16. Hol L., van Leerdam M.E., van Ballegooijen M., et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010, 59:62-68.
17. Guittet L., Bouvier V., Mariotte N., et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007, 56:210-214.
18. van Roon AH, Goede SL, van Ballegooijen M, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut; , in press. http://www.ncbi.nlm.nih.gov/pubmed/22387523.
19. Denters M.J., Deutekom M., Bossuyt P.M., et al. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology 2012, 142:497-504.
20. Zappa M., Castiglione G., Paci E., et al. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience. International Journal of Cancer 2001, 92:151-154.
21. Castiglione G., Visioli C.B., Ciatto S., et al. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme. British Journal of Cancer 2007, 96:1750-1754.
22. Zorzi M., Fedato C., Grazzini G., et al. High sensitivity of five colorectal screening programmes with faecal immunochemical test in the Veneto Region, Italy. Gut 2011, 60:944-949.
23. Morikawa T., Kato J., Yamaji Y., et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005, 129:422-428.
24. Nakama H., Zhang B., Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. European Journal of Cancer 2001, 37:398-401.
25. Rozen P., Comaneshter D., Levi Z., et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010, 116:2115-2125.
26. van Roon A.H., Wilschut J.A., Hol L., et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clinical Gastroenterology and Hepatology 2011, 9:333-339.
27. Guittet L., Bouvier V., Mariotte N., et al. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. International Journal of Cancer 2009, 125:1127-1133.
28. Grazzini G., Visioli C.B., Zorzi M., et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening?. British Journal of Cancer 2009, 100:259-265.
29. Guittet L., Bouvier V., Guillaume E., et al. Colorectal cancer screening: why immunochemical, fecal occult blood test performs as well with either one or two samples. Digestive and Liver Disease 2012, 10.1016/j.dld.2012.03.005.
30. Castiglione G., Grazzini G., Miccinesi G., et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. Journal of Medical Screening 2002, 9:99-103.
31. Faivre J., Dancourt V., Manfredi S., et al. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme. Digestive and Liver Disease 2012, 10.1016/j.dld.2012.03.015.
32. Hol L., Wilschut J.A., van Ballegooijen M., et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. British Journal of Cancer 2009, 100:1103-1110.
33. van Rossum L.G., van Rijn A.F., Laheij R.J., et al. Cut off value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. British Journal of Cancer 2009, 101:1274-1281.
34. Dancourt V., Lejeune C., Lepage C., et al. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. European Journal of Cancer 2008, 44:2254-2258.
35. Patnick J., Segnan N., Von Karsa L. European guidelines for quality assurance in colorectal cancer screening 2010, IARC, Lyon.
36. Berchi C., Guittet L., Bouvier V., Launoy G. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. International Journal of Technology Assessment in Health Care 2010, 26:48-53.
37. van Rossum L.G., van Rijn A.F., Verbeek A.L., et al. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. International Journal of Cancer 2011, 128:1908-1917.
38. Wilschut J.A., Hol L., Dekker E., et al. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011, 141:1648-1655.
39. Sobhani I., Alzahouri K., Ghout I., et al. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Diseases of the Colon and Rectum 2011, 54:876-886.
40. Heitman S.J., Hilsden R.J., Au F., et al. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Medicine 2010, 7:e1000370.
41. Hassan C., Benamouzig R., Spada C., et al. Cost effectiveness and projected national impact of colorectal cancer screening in France. Endoscopy 2011, 43:780-793.